mirvetuximab
ImmunoGen
['ovarian', 'mirvetuximab', 'gyn']
treatment with mirvetuximab soravtansine-gynx reduced the risk of disease progression or death by 35% vs investigator s choice of chemotherapy in a population diagnosed with fr high, platinum-resistant ovarian cancer. #gyncsm #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.